Outcomes and Readmissions After Continuous Flow Left Ventricular Assist Device: Heartmate II Versus Heartware Ventricular Assist Device

Tuncer, O.; KEMALOĞLU, CEMAL; ERBASAN, OZAN; GÖLBAŞI, İLHAN; TÜRKAY, CENGİZ; BAYEZİD, ÖMER

doi:10.1016/j.transproceed.2016.03.056

Outcomes and Readmissions After Continuous Flow Left Ventricular Assist Device: Heartmate II Versus Heartware Ventricular Assist Device

Copy For Citation

Tuncer O. N., KEMALOĞLU C., ERBASAN O., GÖLBAŞI İ., TÜRKAY C., BAYEZİD Ö.

TRANSPLANTATION PROCEEDINGS, vol.48, no.6, pp.2157-2161, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 48 Issue: 6
Publication Date: 2016
Doi Number: 10.1016/j.transproceed.2016.03.056
Journal Name: TRANSPLANTATION PROCEEDINGS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.2157-2161
Akdeniz University Affiliated: Yes

Abstract

Introduction. Donor organ shortage is still a problem for heart transplantation. Only 10% of patients in waiting list undergo heart transplantation. Over the last 5 years, 2 different continuous flow pumps, the HeartMate II and the HeartWare, have been successful clinically in the alternative treatment of patients with end-stage heart disease.